Get started
Work

MM-1100: Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent–Exposed Subgroup

Year: 2026
Type: conference-abstract
DOI: 10.1016/s2152-2650(26)02985-x
Authors: Al-Ola Abdallah, Abhinav Chandra, María-Victoria Mateos, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Sebastian Grosicki, Hanlon Sia, Marcelo Pitombeira de Lacerda, Hena Baig, Benga Kazeem, Tom Jiang, Stewart Wetmore, Vania Hungria
Institutions: University of Kansas Medical Center, Yuma Oncology Center, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Medical University of Lodz, Medical University of Lublin, Botkin Hospital, Royal North Shore Hospital, The University of Sydney, Royal Prince Alfred Hospital, University of Ostrava, University Hospital Ostrava, Medical University of Silesia, Universidade da Região de Joinville, GlaxoSmithKline (Canada), GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), São Germano Oncologia
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7204703386
Cites:
Cited by:
Related to: 10